Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares.

Jefferies analyst Tycho Peterson raised the firm’s price target on Exact Sciences (EXAS) to $85 from $84 and keeps a Buy rating on the ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Revenue: US$708.7m (up 13% from 3Q 2023). Net loss: US$38.2m (down from US$794.0k profit in 3Q 2023). US$0.21 loss per share (down from US$0.004 profit in 3Q 2023). Revenue missed analyst ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Madison-based Exact Sciences Corp. on Tuesday reported third-quarter results worse than analysts expected. The biomedical giant best known for its Cologuard at-home colon cancer screening test ...

Angry fans were quick to point out that Arsenal escaped punishment for the exact same offence that saw Aston Villa defender Tyrone Mings concede his bizarre penalty against Club Brugge on ...